Literature DB >> 8906026

Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome.

P De Potter1, C L Shields, J A Shields, J R Cater, L W Brady.   

Abstract

OBJECTIVES: To assess the effect of plaque radiotherapy on the visual acuity of patients with juxtapapillary choroidal melanoma and to determine the clinical predictive factors for radiation retinopathy, radiation papillopathy, local tumor recurrence, and distant metastasis.
DESIGN: A retrospective review of the medical records of 93 patients with juxtapapillary choroidal melanoma who were treated initially with plaque radiotherapy.
RESULTS: During a mean follow-up of 78 months, radiation retinopathy developed in 81 patients (87%) and radiation papillopathy developed in 48 patients (52%) after a mean interval of 21 and 27 months, respectively. The univariate variables that were significant predictors of radiation retinopathy were history of diabetes mellitus (P = .05) and use of a notched radioactive plaque (P = .04). The factors predictive of radiation papillopathy were age (> 45 years; P = .01), history of diabetes mellitus (P = .05), mushroom-shaped tumor configuration (P = .006), and nasal location of the tumor (P = .04). By using Kaplan-Meier survival curves, we found that the proportion of the 93 patients with radiation retinopathy was 87 (94%) at 5 years and with radiation papillopathy was 53 (57%) at 5 years. By using life-table analysis, we found that the proportion of the 93 patients who experienced a decrement of at least 3 lines of visual acuity was 67 (72%) by 50 to 60 months. Local tumor recurrence was documented in 14 patients (15%) after a mean interval of 41 months. The age of the patient (< 35 years; P = .02) and the superior (P = .004) and inferior (P = .05) locations of the tumor were predictive of local tumor recurrence. Distant metastasis developed in 11 patients (12%) after a mean interval of 44 months. The factors predictive of distant metastasis were a tumor with a basal diameter larger than 6.0 mm (P = .05), the superior location of the tumor (P = .01), and local tumor recurrence (P < .001).
CONCLUSION: Based on these observations, plaque radiotherapy remains a potential option vs enucleation for the management of juxtapapillary choroidal melanoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906026     DOI: 10.1001/archopht.1996.01100140557006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Finger's "slotted" eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours.

Authors:  Paul T Finger
Journal:  Br J Ophthalmol       Date:  2007-02-27       Impact factor: 4.638

3.  Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.

Authors:  John V Hegde; Tara A McCannel; Colin A McCannel; James Lamb; Pin-Chieh Wang; Darlene Veruttipong; Robert Almanzor; D Jeffrey Demanes; Mitchell Kamrava
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-09       Impact factor: 3.117

4.  Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma.

Authors:  Andrea Russo; Michela Laguardia; Bertil Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-23       Impact factor: 3.117

5.  Postradiation Optic Atrophy Is Associated With Intraocular Pressure and May Manifest With Neuroretinal Rim Thinning.

Authors:  Lauren A Dalvin; Christopher L Deufel; Kimberly S Corbin; Ivy A Petersen; Timothy W Olsen; Gavin W Roddy
Journal:  J Neuroophthalmol       Date:  2021-11-11       Impact factor: 4.415

6.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

7.  Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

8.  Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Authors:  Nisha V Shah; Samuel K Houston; Arnold M Markoe; William Feuer; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2012-10-29

9.  Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience.

Authors:  Aaron Wagner; Andy Chen; Taylor Cook; David Faber; Kirk Winward; William Sause
Journal:  ISRN Ophthalmol       Date:  2014-03-09

10.  Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas.

Authors:  Fariba Ghassemi; Shahab Sheibani; Mojtaba Arjmand; Hosein Poorbaygi; Emad Kouhestani; Siamak Sabour; Farhad Samiei; Akbar Beiki-Ardakani; Mahmood Jabarvand; Ali Sadeghi Tari
Journal:  Clin Ophthalmol       Date:  2020-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.